EZH2 and prostate carcinoma: Indeed, after BR-DIM (metabolite 3,3′–diindolylmethane) treatment of prostate cancer cells, let-7c is up-regulated and EZH2 is down-regulated, which hampers the self-renewal and clonogenic properties of prostate cancer cells (79, 80).